Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Childhood Cancers

The Division of Hematology and Oncology at Monroe Carell Jr. Children's Hospital at Vanderbilt includes a dedicated faculty and staff who work together as a team in the diagnosis and treatment of children with cancer or blood diseases. The division also supports a variety of clinical and research programs, a consultation service, and a fellowship training program.

Clinical Trials for Pediatric Cancers

22 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

COGAHOD04B1

10/05/2011

AHOD04B1 - Hodgkin Disease (HD) Banking Study

Basic Science

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

COGAALL05B1

12/01/2006

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Basic Science

COGANHL04B1

09/14/2006

Rare and Cutaneous Non-Hodgkin Lymphoma Registry

Diagnostic

VICCSAR1275

03/21/2013

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Health Services Research

VICCREACH1447

04/16/2014

Retinoblastoma Survivor Study (RBSS)

Other

VICCPED0995

02/18/2010

Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants

Other

VICCPED0974

09/10/2009

Avoidance of Sun Exposure in Patients who Have Had Allogenic Stem Cell Transplants: Effects on Vitamin D Levels and Bone Turnover Markers

Other

VICCPED0710

03/16/2007

Long Term Effects for Childhood Cancer Survivors

Other

COGALTE03N1

04/20/2005

Key Adverse Events after Childhood Cancer

Prevention

VICCPED12112

01/04/2013

NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Supportive Care

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Supportive Care

VICCPED0921

05/01/2009

Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD.

Treatment

COGANBL1232

08/20/2014

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Treatment

VICCNCPED1414

04/24/2014

HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus

Treatment

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Treatment

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Treatment

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum

Treatment

COGACNS0821

10/08/2011

ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Treatment

COGACNS0831

05/12/2011

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.

Treatment

COGAALL0932

11/11/2010

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

Treatment

COGAALL0631

09/09/2008

A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy =/+ FLT3 Inhibition